Quarterly report pursuant to Section 13 or 15(d)

SEGMENT REPORTING (Tables)

v3.20.1
SEGMENT REPORTING (Tables)
3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Summary Statement of Operations for the three months ended March 31, 2020:


   

BioSig

   

ViralClear

         
   

Technologies, Inc

   

Pharmaceuticals, Inc.

   

Total

 

Operating expenses:

                       

Research and development

  $ 1,327,003     $ 3,599,711     $ 4,926,714  

General and administrative

    3,819,438       4,035,782       7,855,220  

Depreciation and amortization

    21,015       -       21,015  

    Total operating expenses

    5,167,456       7,635,493       12,802,949  
                         

Loss from Operations

    (5,167,456 )     (7,635,493 )     (12,802,949 )
                         

Other income:

                       

Interest income

    25,411       14,165       39,576  
                         

Net loss

    (5,142,045 )     (7,621,328 )     (12,763,373 )
                         

Preferred stock dividend

    (4,618 )     -       (4,618 )
                         

Net loss attributable to common stockholder

    (5,146,663 )     (7,621,328 )     (12,767,991 )
                         

Non-controlling interest

    -       1,427,813       1,427,813  
                         

Net loss attributable to BioSig Technologies, Inc.

  $ (5,146,663 )   $ (6,193,515 )   $ (11,340,178 )